Since the introduction of the BIOSECURE Act in January 2024, the pharmaceutical industry has been closely monitoring its implications. The proposed legislation has prompted companies to explore CDMOs outside China, prepare for higher drug development costs, and address potential impacts on those reliant on federal grants from agencies like the NIH and the Department of Defense.
Precision for Medicine’s Anshul Mangal sat down with Pharmaceutical Technology to discuss about the impact of BIOSECURE Act, outlining steps companies can take to mitigate its impact.
Bracing for Impact
Precision for Medicine’s Anshul Mangal sat down with Pharmaceutical Technology to discuss about the impact of BIOSECURE Act, outlining steps companies can take to mitigate its impact.
In his interview, Anshul shares expert insights on:
- The alternatives to using China-based contract development and manufacturing organizations (CDMOs).
- Whether alternative companies can offer goods and services at a cost comparable to those offered by companies like WuXi, considering the US Congressional Budget Office's (CBO) assessment.
- The impact on the drug approval process for companies preparing data packages using data collected by Chinese CDMOs.
- What companies can do to mitigate the impact of the BIOSECURE Act.
Read Anshul’s full interview with Pharmaceutical Technology’s Phalguni Deswal in “Drug development costs predicted to soar as BIOSECURE Act gains momentum.”
